Medium chain fatty acids for use in the prevention or treatment of cardiac enlargement and/or valvular heart disease
Medium chain fatty acids or a composition comprising medium chain fatty acids for use in the prevention or treatment of cardiac enlargement, valvular heart disease and/or a condition associated with either of the foregoing in a human.
1. A method for reduction of risk of or treatment of cardiac enlargement and/or valvular heart disease and/or a condition associated with at least one of the cardiac enlargement or the valvular heart disease in a human subject in need thereof, the method comprising:
orally administering to the human subject a composition comprising one or more medium chain fatty acids each in a form selected from the group consisting of (i) triacylglycerides in which each of the triacylglycerides comprises two or three of the medium chain fatty acids, (ii) monoacylglycerides, (iii) diacylglycerides and (iv) any mixture thereof,
the composition comprising at least 5 wt % of medium chain triglyceride (MCT), at least 0.3 wt % of docosahexaenoic acid (DHA), at least 0.4 wt % of eicosapentaenoic acid (EPA), at least 2 wt % of lysine, at least 2 wt % of methionine and cysteine combined, at least 0.15 wt % of magnesium, at least 0.9 IU/g of vitamin E, and at least 0.2 wt % of taurine, wherein the MCT comprises more than 40% of total C8 and more than 50% of total C10, and
the composition is administered simultaneously, sequentially or separately to a medicine intended to treat and/or reduce the risk of the cardiac enlargement and/or the condition associated therewith and/or a condition that increases the risk of the cardiac enlargement and/or the valvular heart disease in the human subject.
2. The method according to claim 1 , wherein the valvular heart disease is selected from the group consisting of mitral valve insufficiency, aortic valve insufficiency, tricuspid valve insufficiency, and combinations thereof.
3. The method according to claim 1 , wherein the condition associated with the cardiac enlargement and/or the valvular heart disease is selected from the group consisting of thrombosis, irregular heart rhythms, angina, heart attack, high blood pressure or hypertension, cardiac arrest, heart failure, and combinations thereof.
4. The method according to claim 1 , wherein the one or more medium chain fatty acids are selected from the group consisting of C6:0, C8:0, C10:0, C12:0, and combinations thereof.
5. The method according to claim 1 , wherein the composition is administered for a period of more than 3 months.
6. The method according to claim 1 , wherein the human subject is at risk of the cardiac enlargement and/or the valvular heart disease.
7. The method according to claim 6 , wherein the human subject at risk of the cardiac enlargement and/or the valvular heart disease also has a condition selected from the group consisting of high blood pressure, hypertension, hypertrophic cardiomyopathy, heart muscle inflammation, myocarditis, thyroid disease, a disease of the heart valve, a heart attack, a cardiac infarction, and combinations thereof.
8. The method according to claim 7 , wherein the cardiac enlargement or the valvular heart disease is age-related.
9. The method according to claim 1 , wherein the human subject is a human adult.
10. The method according to claim 1 , wherein the composition further comprises carnitine.
11. The method according to claim 1 , wherein the composition is a product selected from the group consisting of a medicament, a food product, a medical food, an oral nutritional supplement, a nutritional composition and a supplement to a food product.
12. The method according to claim 1 , wherein the composition further comprises one or more additional triglycerides in which less than three fatty acids of each of the one or more additional triglycerides is a medium chain fatty acid.
13. The method according to claim 1 , wherein the composition is a food product selected from the group consisting of a health drink, a ready-made drink, a soft drink, a juice, a milk-shake, a yogurt drink, a smoothie, a soy-based drink, a bar, and combinations thereof.
14. A composition comprising one or more medium chain fatty acids each in a form selected from the group consisting of (i) triacylglycerides in which each of the triacylglycerides comprises two or three of the medium chain fatty acids, (ii) monoacylglycerides, (iii) diacylglycerides and (iv) any mixture thereof,
the composition comprising at least 5 wt % of medium chain triglyceride (MCT), at least 0.3 wt % of DHA, at least 0.4% of EPA, at least 2 wt % of lysine, at least 2 wt % of methionine and cysteine combined, at least 0.15 wt % of magnesium, at least 0.9 IU/g of vitamin E, and at least 0.2% of taurine, wherein the MCT comprises more than 40% of total C8 and more than 50% of total C10, and
the composition is formulated designed to be orally administered to a human subject simultaneously, sequentially or separately to a medicine intended to treat and/or reduce the risk of the cardiac enlargement and/or the condition associated therewith and/or a condition that increases the risk of the cardiac enlargement and/or the valvular heart disease in the human subject.
15. The composition according to claim 14 , wherein the composition is selected from the group consisting of a medicament, a food product, a medical food, an oral nutritional supplement, a nutritional composition and a supplement to a food product.
16. The composition according to claim 14 , wherein the composition is a food product selected from the group consisting of a health drink, a ready-made drink, a soft drink, a juice, a milk-shake, a yogurt drink, a smoothie, a soy-based drink, a bar, and combinations thereof.